NYR-BI03

NYR-BI03 is a small-molecule inhibitor specifically targeting the Transient Receptor Potential Canonical (TRPC) ion channels subtypes 3, 6, and 7.  It was developed using a rational drug discovery approach.

This innovative therapeutic candidate aims to effectively prevent cardiac damage and secondary brain injury by inhibiting excessive calcium ion accumulation, a crucial mechanism underlying cellular death and tissue injury.

The TRPC family comprises seven distinct members (TRPC1 to TRPC7), organised into four subgroups based on structural homology: TRPC1, TRPC2, TRPC4/5, and TRPC3/6/7.  Among these, the TRPC3/6/7 subfamily is broadly expressed in various tissues and exhibits increased expression levels during pathological conditions. Overactivation of these channels (TRPC3/6/7) in disease states results in excessive intracellular calcium accumulation, particularly affecting neurons and cardiomyocytes, thereby promoting cell death.

Nyrada’s preclinical studies have demonstrated that NYR-BI03 substantially reduced secondary brain injury by approximately 42% and offered significant cardioprotection, with an 86% improvement observed in myocardial reperfusion injury models.

NYR-BI03 is covered by a composition-of-matter patent application, underscoring its innovative chemical structure and promising therapeutic potential.